Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1552951

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1552951

Carcinoembryonic Antigen Market Size, Share & Trends Analysis Report By Type (Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer), By Gender, By Product, By Test, By End Use, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 90 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Carcinoembryonic Antigen Market Growth & Trends:

The global carcinoembryonic antigen market size is expected to reach USD 2.95 billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Constant technological advancements pertaining to the development of novel biomarkers which can be used in combination with other biomarkers is expected to boost usage rates over the forecast period. Furthermore, the increasing prevalence of cancer is expected to heighten the demand for effective diagnostic tools. According to the WHO estimates in 2012, global cancer incidences were nearly 14.1 million, which include 6.7 million female patients and 7.4 million male patients. Increasing demand for minimally invasive diagnostics procedures is also expected to play a vital role in determining market growth. Key advantages associated with minimally invasive diagnostics procedures include elevated patient satisfaction levels as they entail minor incision wounds. In addition, these procedures involve relatively lesser hospital stays and therefore, are economically viable and involve fewer post procedure complications.

Carcinoembryonic Antigen Market Report Highlights:

  • Colorectal cancer was one of the largest revenue generating application segment of the carcinoembryonic antigen market and was estimated at USD 193.32 million in 2023. Increasing prevalence of colorectal cancer and usage of carcinoembryonic antigen tests at various stages is one of the critical factors accounting for its large share. For instance, in 2012, new cases of colorectal cancer were estimated to be over 93,000 and death due to colorectal cancer is expected to be over 49,700 in the U.S alone.
  • Carcinoembryonic antigen based breast cancer diagnosis is identified as the most lucrative application segment of the market. The market is driven by factors such as growing number of female population above 50 years, growing demand for Hormone Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient awareness levels and the presence of favorable government initiatives are expected to improve treatment rates over the forecast period.
  • North America was the largest regional market in 2023 owing to, the presence of high incidence rates, presence of favorable reimbursement framework, and high consumer awareness levels coupled with relatively higher healthcare expenditure levels.
  • Asia Pacific is anticipated to witness the most lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and improving patient awareness levels are some factors accounting for this rapid growth.
Show more
Product Code: 978-1-68038-425-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Carcinoembryonic Antigen Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Carcinoembryonic Antigen Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Carcinoembryonic Antigen Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Carcinoembryonic Antigen Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Colorectal Cancer
    • 4.3.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Pancreatic Cancer
    • 4.4.1. Pancreatic Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Ovarian Cancer
    • 4.5.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Thyroid Cancer
    • 4.7.1. Thyroid Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carcinoembryonic Antigen Market: Gender Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Carcinoembryonic Antigen Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Male
    • 5.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Female
    • 5.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carcinoembryonic Antigen Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Carcinoembryonic Antigen Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. CD66a
    • 6.3.1. CD66a Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CD66b
    • 6.4.1. CD66b Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CD66c
    • 6.5.1. CD66c Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CD66d
    • 6.6.1. CD66d Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. CD66f
    • 6.7.1. CD66f Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carcinoembryonic Antigen Market: Test Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Carcinoembryonic Antigen Market: Test Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Molecular Tests
    • 7.3.1. Molecular Tests Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Serology Tests
    • 7.4.1. Serology Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Carcinoembryonic Antigen Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Carcinoembryonic Antigen Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 8.3. Hospitals
    • 8.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Laboratories
    • 8.4.1. Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Others
    • 8.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Carcinoembryonic Antigen Market: Regional Estimates & Trend Analysis

  • 9.1. Carcinoembryonic Antigen Market Share, By Region, 2023 & 2030 (USD Million)
  • 9.2. North America
    • 9.2.1. North America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. China Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Japan Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Australia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Saudi Arabia Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Carcinoembryonic Antigen Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. Quest Diagnostics Incorporated
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. F. Hoffmann-La Roche Ltd
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Creative Diagnostics
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Aviva Systems Biology Corporation
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. Abbott
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Laboratory Corporation of America Holdings
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. Merck KGaA
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Omega Diagnostics Ltd
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives
    • 10.4.9. Boster Biological Technology
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments/ Strategic Initiatives
    • 10.4.10. Lee BioSolutions
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!